Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 2, 2012, Pages 341-350

  Thertulien, R ^a   Manikhas, G M ^b   Dirix, L Y ^c   Vermorken, J B ^d   Park, K ^e   Jain, M M ^f   Jiao, J J ^g   Natarajan, J ^g   Parekh, T ^g   Zannikos, P ^g   Staddon, A P ^h  

^a Cancer Centers of North Carolina   (United States)

^b City Clinical Oncology Dispensary   (Russian Federation)

^c SINT AUGUSTINUS HOSPITAL   (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e Samsung Medical Center   (South Korea)

^f Ruby Hall Clinic ^*  (India)

^g JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^h Pennsylvania Oncology Hematology Associates   (United States)

Author keywords

Anti tumor; ECG; Malignancies; QTc interval; Trabectedin

Indexed keywords

DEXAMETHASONE; PLACEBO; TRABECTEDIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER RELAPSE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DISEASE COURSE; DIZZINESS; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SAFETY; ELECTROCARDIOGRAM; ENZYME DEFECT; FATIGUE; FEMALE; FEVER; HEART RATE; HUMAN; LEUKOPENIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; OROPHARYNX CANCER; OVARY CANCER; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RISK FACTOR; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTHENIA; DIOXOLES; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; NEOPLASMS; SINGLE-BLIND METHOD; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 84856753761     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1697-6     Document Type: Article

References (23)

1. L Boudou M Baconnier J-Y Blay C Lombard-Bohas PA Cassier 2009 Trabectedin for the management of soft-tissue sarcoma Expert Rev Anticancer Ther 9 727 737 19496709 10.1586/era.09.28 1:CAS:528:DC%2BD1MXmvFagur4%3D
2. NJ Carter SJ Keam 2007 Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer Drugs 67 2257 2276 17927287 10.2165/00003495-200767150-00009 1:CAS:528:DC%2BD2sXhsVWkt7fP (Pubitemid 47557097)
3. EMEA Yondelis (2010) Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPARProduct-Information/ human/000773/WC500045832.pdf. Accessed 27 Aug 2010
4. JJ Perez-Ruixo P Zannikos S Hirankarn K Stuyckens EA Ludwig A Soto-Matos L Lopez-Lazaro JS Owen 2007 Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients Clin Pharmacokinet 46 867 884 17854236 10.2165/00003088-200746100-00005 1:CAS:528:DC%2BD2sXht1yktr%2FJ (Pubitemid 47443311)
5. JH Beumer L Lopez-Lazaro JH Schellens JH Beijnen O van Tellingen 2009 Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743) Curr Clin Pharmacol 4 38 42 19149499 10.2174/157488409787236047 1:CAS:528:DC%2BD1MXlt1Gnsr8%3D
6. M Vermeir A Hemeryck F Cuyckens A Francesch M Bockx J Van Houdt K Steemans G Mannens P Aviles R De Coster 2009 In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping Biochem Pharmacol 77 1642 1654 19426702 10.1016/j.bcp.2009.02.020 1:CAS:528:DC%2BD1MXksVSksLc%3D
7. I Gussak J Litwin R Kleiman S Grisanti J Morganroth 2004 Drug-induced cardiac toxicity: emphasizing the role of electrocardiography in clinical research and drug development J Electrocardiol 37 19 24 15132365 10.1016/j.jelectrocard.2003.11.003 (Pubitemid 38168825)
8. M Roden 2004 Drug induced prolongation of the QT interval N Engl J Med 350 1013 1022 14999113 10.1056/NEJMra032426 1:CAS:528:DC%2BD2cXhvFGjs7Y%3D (Pubitemid 38269278)
9. RR Shah 2002 The significance of QT interval in drug development Br J Clin Pharmacol 54 188 202 12207642 10.1046/j.1365-2125.2002.01627.x 1:CAS:528:DC%2BD38XnvVWis7o%3D (Pubitemid 35024944)
10. B Darpo T Nebout PT Sager 2006 Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the international conference on harmonization of technical requirements for registration of pharmaceuticals for human use E14 guideline J Clin Pharmacol 46 498 507 16638733 10.1177/0091270006286436 1:CAS:528:DC%2BD28Xksl2ms7w%3D
11. PA Cassier A Dufresne JY Blay J Fayette 2008 Trabectedin and its potential in the treatment of soft tissue sarcoma Ther Clin Risk Manag 4 109 116 18728699 1:CAS:528:DC%2BD1cXks1Sksrg%3D (Pubitemid 351460936)
12. C Sessa F De Braud A Perotti J Bauer G Curigliano C Noberasco F Zanaboni L Gianni S Marsoni J Jimeno M D'Incalci E Dall'o N Colombo 2005 Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails J Clin Oncol 23 1867 1874 15774779 10.1200/JCO.2005.09.032 1:CAS:528: DC%2BD2MXjt1Ckurc%3D (Pubitemid 46211364)
13. GD Demetri SP Chawla M von Mehren P Ritch LH Baker JY Blay KR Hande ML Keohan BL Samuels S Schuetze C Lebedinsky YA Elsayed MA Izquierdo J Gomez YC Park A Le Cesne 2009 Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules J Clin Oncol 27 4188 4196 19652065 10.1200/JCO.2008.21.0088 1:CAS:528:DC%2BD1MXhtF2jtLrL
14. S Gurtler L Goldstein S Delprete 2005 Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration J Clin Oncol 23 625
15. BJ Monk TJ Herzog SB Kaye CN Krasner JB Vermorken FM Muggia E Pujade-Lauraine AS Lisyanskaya AN Makhson J Rolski VA Gorbounova P Ghatage M Bidzinski K Shen HY Ngan IB Vergote JH Nam YC Park CA Lebedinsky AM Poveda 2010 Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 3107 3114 20516432 10.1200/JCO.2009.25.4037 1:CAS:528: DC%2BC3cXpslajt7k%3D
16. TA Puchalski DP Ryan R Garcia-Carbonero GD Demetri L Butkiewicz D Harmon MV Seiden RG Maki L Lopez-Lazaro J Jimeno C Guzman JG Supko 2002 Pharmacokinetics of ecteinascidin 743 administered as a 24 h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity Cancer Chemother Pharmacol 50 309 319 12357306 10.1007/s00280-002-0498-3 1:CAS:528:DC%2BD38XnsVamtLY%3D
17. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (2005) The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: E14. Geneva, Switzerland (updated 12 May 2005). Available from: http://www.ich.org/LOB/media/MEDIA1476.pdf
18. DM Bloomfield JT Kost K Ghosh D Hreniuk LA Hickey MJ Guitierrez K Gottesdiener JA Wagner 2008 The effect of moxifloxacin on QTc and implications for the design of thorough QT studies Clin Pharmacol Ther 84 475 480 19238652 10.1038/clpt.2008.33 1:CAS:528:DC%2BD1cXhtFeitbjL
19. M Malik K Hnatkova A Schmidt P Smetana 2009 Electrocardiographic QTc changes due to moxifloxacin infusion J Clin Pharmacol 49 674 683 19451404 10.1177/0091270008330984 1:CAS:528:DC%2BD1MXmvVOrurg%3D
20. M Iwamoto JT Kost GC Mistry LA Wenning SA Breidinger TC Marbury JA Stone KM Gottesdiener DM Bloomfield JA Wagner 2008 Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval J Clin Pharmacol 48 726 733 18441333 10.1177/0091270008318007 1:CAS:528:DC%2BD1cXns1Kit7g%3D (Pubitemid 351713160)
21. R Hulhoven D Rosillon M Letiexhe MA Meeus A Daoust A Stockis 2007 Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study Eur J Clin Pharmacol 63 1011 1017 17891537 10.1007/s00228-007-0366-5 1:CAS:528:DC%2BD2sXhtFGgsLvP (Pubitemid 47561809)
22. DM Bloomfield R Krishna D Hreniuk L Hickey K Ghosh AJ Bergman J Miller MJ Gutierrez R Stoltz KM Gottesdiener GA Herman JA Wagner 2009 A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects J Clin Pharmacol 49 937 946 19602719 10.1177/0091270009337511 1:CAS:528:DC%2BD1MXhtVSqur%2FJ
23. X Zhang M Silkey M Schumacher L Wang H Raval JP Caulfield 2009 Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested J Clin Pharmacol 49 534 539 19287043 10.1177/0091270008330158 1:CAS:528:DC%2BD1MXlsFWmu78%3D